Science & Society


The Bi4S Course has participants from over 40 countries making it a truly global educational initiative on Genomics and Bioinformatics for School Students.



The IndiGen progarmme and the IndiGenome Card

The IndiGen programme aims to undertake whole genome sequencing of thousands of individuals representing diverse ethnic groups from India. The objective is to enable genetic epidemiology and develop public health technologies applications using population genome data.

The Council for Scientific and Industrial Research has sequenced the entire genomes of 1008 Indians in six months, under a mission that was aimed at demonstrating capability and scalability of Indian research institutions. This initiative, called IndiGen, was undertaken by two CSIR institutions — Institute of Genomics and Integrative Biology (IGIB), Delhi and Centre for Cellular and Molecular Biology (CCMB), Hyderabad.


Read more on the IndiGen Programme

#GENESCoV2

Genetic Epidemiology of SARS-CoV-2 in Kerala

A unique partnership between the Department of Health & Family Welfare, Government of Kerala, National health Mission Kerala, CSIR Institute of Genomics & Integrative Biology (CSIR-IGIB) and various clinical and public health centers in Kerala aimed at providing insights into the genetic epidemiology of COVID-19 in Kerala

Learn more https://genescov2.genomes.in/

ENABLING ACCESS TO GENETIC DISEASE DIAGNOSIS

March 2018: The know-how for 27 genetic tests for diagnosis of prevalent genetic diseases/traits have been licensed to Dr Lal Path Labs one of the largest clinical diagnostic chains in India.

These tests were developed under the Genomics and other Omics to Enable Medical Decisions (GOMED) programme, a unique outreach programme of CSIR-IGIB and funded through a CSIR Fast-Track Translation (FTT) Grant


Find more Information

More about Dr Lal Path Labs


Rare Disease Diagnostics features in CSIR's top 10 innovations in 2018


The Council of Scientific and Industrial Research has had an exciting 2018 where India’s first biofuel powered flight, aerospace technology, research in rare diseases, stroke, artificial intelligence and water disinfection have seen a major boost. Ranked 9th in the world, amongst a total of 1,207 government institutions, according to Scimago Institutions ranking, the institute has come a long way. These are ten exciting achievements which are going to take shape in the year 2019.

With 72,611,605 million Indians suffering from rare diseases there is a need for cost effective genetic tests which can be provided to the people. CSIR is working with a private company for licensing of 27 approved genetic tests which can be used commercially and will be launched in 2019.


https://www.deccanchronicle.com/nation/current-affairs/261218/csir-stands-tall-with-10-innovations-in-2018.html

BENCH TO BEDSIDE FOR MITOCHONDRIAL DISEASE DIAGNOSIS


April 2016: The know-how for mitochondrial sequence analysis has been transferred to Eurofins Clinical Genetics India Ltd (Subsidiary of Eurofins Scientific, a world leader in testing services).

The product is available in the Indian market.

Find more Information

More about Eurofins Clinical Genetics India


Next generation Sequencing based approach for diagnosis of Mitochondrial Disorders

The diverse clinical spectrum of diseases manifested by mitochondrial dysfunction demands proper interpretation and analysis of mtDNA variants. mit-o-matic is a tool designed to provide clinically relevant information distributed in disparate resources for understanding and annotating mtDNA variations.

Publication: Vellarikkal et al (2015) Human Mutation

CSIR-IGIB Partners with Genique for Genomic Applications in Rare Genetic Diseases

Though rare genetic diseases are individually rare and encompass a spectrum of over 7000 diseases, together they amount to a significant number in the population. It is estimated that over 300 million people suffer from one or other rare genetic disease in the world. India shares a significant proportion of this, with estimates that it is home to over 30 million people with rare genetic diseases. Without a national programme for genetic diseases, and neonatal screening, many of the diseases remain undiagnosed. The diversity in social, cultural and marriage practices would also mean that many diseases run in families/communities, in some times significantly impairing the social function of the families, apart from the large economic and emotional burden these families/communities go through.

Addressing the problem of Genetic Diseases in India requires concerted efforts involving patients, clinicians researchers and industry.

CSIR IGIB signed an agreement with Genique Lifesciences to develop Genomics solutions for Genetic Diseases 

CSIR-IGIB partners with Sanofi Genzyme in the area of Rare Genetic Diseases

Though rare genetic diseases are individually rare and encompass a spectrum of over 7000 diseases, together they amount to a significant number in the population. It is estimated that over 300 million people suffer from one or other rare genetic disease in the world. India shares a significant proportion of this, with estimates that it is home to over 30 million people with rare genetic diseases. Without a national programme for genetic diseases, and neonatal screening, many of the diseases remain undiagnosed. The diversity in social, cultural and marriage practices would also mean that many diseases run in families/communities, in some times significantly impairing the social function of the families, apart from the large economic and emotional burden these families/communities go through.

In furtherence of SANOFI GENZME’s commitment to patients of rare diseases and the CSIR–INSTITUTE OF GENOMICS & INTEGRATIVE BIOLOGY‘s aim to initiate a unique research program on Genomics for understanding rare diseases, Sanofi Genzyme, a division of Sanofi-Synthelabo (India) Pvt. Limited hereby agrees to collaborate with the CSIR–INSTITUTE OF GENOMICS & INTEGRATIVE BIOLOGY for a partnership in the area of clinical genomics & rare genetic diseases.